New Haven, CT 的 胃癌 臨床試驗
8 項針對 胃癌 的研究正在 New Haven（約 30 英里範圍內）及其周邊地點尋找參與者。開啟研究以查看參與資格及聯絡研究團隊的方式。
官方研究文本（英文）
正在為研究招募對象嗎？將此頁面置頂展示 — $99 / 30 天 →
A Study of HER3-DXd in Subjects With Locally Advanced or Metastatic Solid Tumors
招募中2 期
- Yale Cancer Center, New Haven
A Phase 1 Study of IM-1617 in Participants With Advanced Cancer
招募中1 期
- Yale Cancer Center, New Haven
Anti-Ly6E Exatecan ADC M7437 in Advanced Solid Tumors
招募中1 期
- Yale University - Yale University School of Medicine, New Haven
Phase 3 Study of Cadonilimab Combined With Chemotherapy vs Chemotherapy in Combination With or Without Nivolumab for the 1L Treatment of Participants With HER2-negative, Previously Untreated, Unresectable or Metastatic Gastric/GEJ Adenocarcinoma
招募中3 期
- Yale School of Medicine, New Haven
A Clinical Study to Test if an Investigational Treatment Called BNT326 is Safe and Potentially Beneficial When Used Alone or in Combination With Other Investigational Treatments Such as BNT327, for People With Advanced Malignant Tumors
招募中1/2 期
- Yale University, New Haven
Study of TDXd, Chemotherapy, Pembrolizumab, and Trastuzumab in First-Line Metastatic HER2-Positive Gastric or Gastroesophageal Junction Cancer
招募中3 期
- Yale Cancer Center, New Haven
BAL0891 in Patients With Advanced Solid Tumors or Relapsed or Refractory Acute Myeloid Leukemia
招募中1 期
- Yale New Haven Hospital, New Haven
A Study of PARG Inhibitor ETX-19477 in Patients With Advanced Solid Malignancies
招募中1/2 期
- Yale University, Yale Cancer Center, New Haven
其他城市的 胃癌 試驗
- Houston, TX42 項研究
- Boston, MA32 項研究
- New York City, NY31 項研究
- Nashville, TN28 項研究
- Baldwin Park, CA22 項研究
- Los Angeles, CA22 項研究
- Arlington, VA20 項研究
- Dallas, TX19 項研究
- San Antonio, TX19 項研究
- St. Louis, MO18 項研究
- Grand Rapids, MI18 項研究
- Chicago, IL16 項研究
New Haven 的其他研究
- 非小細胞肺癌41 項研究
- 乳癌38 項研究
- 癌症（所有類型）33 項研究
- 轉移性癌症23 項研究
- 肺癌22 項研究
- 頭頸部鱗狀細胞癌22 項研究
- 卵巢癌21 項研究
- 大腸直腸癌20 項研究
- 前列腺癌20 項研究
- 急性髓系白血病17 項研究
- 酒精使用障礙 (AUD)17 項研究
- 鴉片類藥物過量17 項研究
資料來源：ClinicalTrials.gov，擷取日期 2026年10月6日。各研究自行設定資格標準；由研究團隊決定參與者資格。